title: Therapeutic effects of oral rebamipide and in combination with cimetidine on experimental gastritis in rats.
abstract: The present study evaluated the therapeutic effects of rebamipide alone and in combination with cimetidine on experimental gastritis established by the administration of 5 mM sodium taurocholate (TCA) for 6 months in rats. Morphological and biochemical analyses were performed to determine the effects of rebamipide, administered alone or in combination with cimetidine, on chronic, atrophic and erosive gastritis. Rebamipide and cimetidine were administered to rats as a dietary admixture for 4 weeks after withdrawal of TCA. Rebamipide dose-dependently reduced the total length of the erosion, normalized the mucosal thickness and increased the number of parietal and total cells, and tended to reduce interstitial infiltration of inflammatory cells and proliferation of collagenous fibers. Moreover, histochemical and biochemical studies also showed rebamipide to be effective. Rebamipide increased the PAS-positive mucus and normalized the reduced gastric mucosal SOD activity. The therapeutic effect of rebamipide on the experimental gastritis was enhanced by the combined use of cimetidine. These results suggest that rebamipide has a therapeutic effect on chronic atrophic erosive gastritis induced by TCA, and that the mechanism of the therapeutic effect is partially due to the increase in PAS-positive mucus and gastric mucosal SOD activity. Furthermore, the enhanced effect of the combination therapy of rebamipide with cimetidine was considered to be due to the actions of both cimetidine and rebamipide.
authors.affiliation: Department of Medicine, Hiroshima University School of Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kishimoto
authors.forename: J
authors.initials: J
authors.lastname: Fujimura
authors.forename: H
authors.initials: H
authors.lastname: Machino
authors.forename: T
authors.initials: T
authors.lastname: Shimamoto
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Shimizu
authors.forename: K
authors.initials: K
authors.lastname: Haruma
authors.forename: G
authors.initials: G
authors.lastname: Kajiyama
authors.forename: K
authors.initials: K
authors.lastname: Sakurai
authors.forename: K
authors.initials: K
authors.lastname: Yamasaki
mesh_terms: D000284:Administration, Oral; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005745:Gastric Acidity Determination; D005750:Gastric Juice / Q000187:drug effects; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005757:Gastritis, Atrophic / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013656:Taurocholic Acid
chemical_list: D000897:Anti-Ulcer Agents; D015363:Quinolones; D013656:Taurocholic Acid; D002927:Cimetidine; C052785:rebamipide; D000409:Alanine